Wafik S. El-Deiry: I hope it is helpful to students of all ages to incorporate historical knowledge and progress into current thinking
Wafik S. El-Deiry shared on X:
“Here is a meeting report I wrote in the past which is still fun to read 20 years later (including who spoke). Reflecting back, it is a reminder of where the field of cancer research was in 2004 as it relates to tumor progression and therapeutic resistance. Many of the topics remain extremely relevant in 2024. I hope it is helpful to students of all ages to incorporate historical knowledge and progress into current thinking.”
View additional information.
Source: Wafik S. El-Deiry/X
Wafik El-Deiry, MD, PhD, FACP, FRSM, an American Cancer Society Research Professor, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response.
This has been the most highly cited original work published in Cell. He discovered TRAIL receptor DR5 as a p53 target, and ONC201/TIC10 as a TRAIL pathway, integrated stress response inducer, and cancer therapeutic with efficacy in diffuse midline glioma and other tumors. He was named one of America’s Top Oncologists by the Consumer Res Council of America in 2008 and 2009. He is a practicing physician-scientist specializing in colorectal cancer treatment.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023